Lexology January 15, 2026
On 15 January 2026, Zydus Lifesciences Ltd and Agenus Inc. announced the closing of a deal in which Zydus acquired Agenus’ biologics manufacturing facilities in Emeryville and Berkeley, California, and obtained exclusive rights to develop and commercialise Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program in India and Sri Lanka.
The transaction includes a US$75 million cash payment by Zydus to Agenus for the transfer of the biologics manufacturing facilities, a US$16 million purchase of shares in Agenus by Zydus and up to US$50 million in milestone payments by Zydus to Agenus based on BOT+BAL production orders. Agenus is also eligible to receive a 5% royalty on net sales of BOT+BAL in India and Sri Lanka.
Zydus is...
Today's Sponsors
Today's Sponsor